2019-10-25
NextCell invests in the Danish Cellaviva operations with a new Copenhagen office
NextCell Pharma AB ("NextCell") today announces they are investing for growth in Cellaviva's Danish operations with the opening of a new Copenhagen office.
In October, Cellaviva's new office was opened in Copenhagen, located in Kløvebyen. The Copenhagen office is primarily intended to be a hub for the Danish Cellaviva business with the opportunity to host customers, hold training sessions etc. The purpose is also to enable increased exposure and presence for NextCell in the Öresund region.
[image] [image]
NextCell Pharma AB ("NextCell") today announces they are investing for growth in Cellaviva's Danish operations with the opening of a new Copenhagen office.
In October, Cellaviva's new office was opened in Copenhagen, located in Kløvebyen. The Copenhagen office is primarily intended to be a hub fo...
Read moreRead more2019-10-01
All patients in ProTrans-Repeat are now treated
NextCell Pharma AB ("NextCell") announces that another significant milestone has been reached when the last patient, as part of the ProTrans-Repeat active treatment group, today has received their treatment. This implies that all treatments, related to the two ongoing ProTrans studies, have been completed.
NextCell is conducting two parallel clinical trials with the drug candidate ProTrans, with the aim to treat diabetes type-1. ProTrans-Repeat, which was initiated in May 2019, is a continuation trial of ProTrans-1 dose escalation part with the aim of maximizing data collection on repeated
NextCell Pharma AB ("NextCell") announces that another significant milestone has been reached when the last patient, as part of the ProTrans-Repeat active treatment group, today has received their treatment. This implies that all treatments, related to the two ongoing ProTrans studies, have been ...
Read moreRead more2019-09-24
Last patient, last visit completed in the dose escalation part
NextCell Pharma AB (NextCell) is today announcing that the last patient in the dose escalation part of the clinical trial ProTrans-1 for diabetes is completed. The last patient was today at the last visit and has now left the trial.
ProTrans-1 is a two-part phase I / II clinical trial where the phase I part evaluates safety for three doses. All nine patients have now been followed up for 12 months and have left the study.
As previously communicated, all 15 patients in the phase II part of ProTrans-1 have been treated and will be followed for 12 months. The second part is randomized,
NextCell Pharma AB (NextCell) is today announcing that the last patient in the dose escalation part of the clinical trial ProTrans-1 for diabetes is completed. The last patient was today at the last visit and has now left the trial.
ProTrans-1 is a two-part phase I / II clinical trial where the p...
Read moreRead more2019-09-12
Update on the ongoing clinical trials
NextCell Pharma AB (NextCell) is today providing a status update regarding its two ongoing clinical trials, presented at the Nordic Life Science days in Malmö. All patients in ProTrans-1 were treated by June 2019 and 8 out of 9 patients in the dose escalation part have already left the trial after 12 months follow-up. The ProTrans-Repeat has included 5 out of 18 patients.
NextCell is conducting two parallel clinical trials with the drug candidate ProTrans, with the aim to treat type-1 diabetes. A single dose of ProTrans is given and the patients own ability to produce insulin is compared
NextCell Pharma AB (NextCell) is today providing a status update regarding its two ongoing clinical trials, presented at the Nordic Life Science days in Malmö. All patients in ProTrans-1 were treated by June 2019 and 8 out of 9 patients in the dose escalation part have already left the trial afte...
Read moreRead more2019-08-16
NextCell Pharma files another patent application
NextCell Pharma AB ("NextCell") today announces that they have filed a new patent application to the Swedish Patent and Registration Office. The patent relates to the Company's proprietary selection algorithm, now with extended and tailored analyses for diseases and conditions affecting the central nervous system.
The application was submitted to the Swedish Patent and Registration Agency on August 15 and is formulated to cover the general production of all types of mesenchymal stem cell products derived from multiple donors and cells selected by the selection algorithm. Furthermore, the
NextCell Pharma AB ("NextCell") today announces that they have filed a new patent application to the Swedish Patent and Registration Office. The patent relates to the Company's proprietary selection algorithm, now with extended and tailored analyses for diseases and conditions affecting the centr...
Read moreRead more2019-07-31
Interim report 2018-09-01 - 2019-05-31
Third quarter report
By "NextCell", “NXTCL” or "Company" is meant NextCell Pharma AB with organization number 556965-8361. “Spotlight" refers to the Spotlight Stock Market (previous AktieTorget). Amount in brackets refer to the corresponding period in the previous year. Note that the Company's fiscal year is September 1 - August 31. This English version is a translation of the Swedish version. The Swedish version is at all time to be seen as the leading document.
Nine months (2018-09-01 until 2019-05-31)
· Operating income amounted to SEK 1 410 055 (527 545).
· Operating result
Third quarter report
By "NextCell", “NXTCL” or "Company" is meant NextCell Pharma AB with organization number 556965-8361. “Spotlight" refers to the Spotlight Stock Market (previous AktieTorget). Amount in brackets refer to the corresponding period in the previous year. Note that the Company's f...
Read moreRead more2019-06-20
Final patient treated in the phase II part of the ProTrans-1 trial
NextCell Pharma AB (NextCell) today treated the last diabetic patient in the phase II part of the ProTrans-1 trial. This means that all patients included in the clinical study have been treated and are now subject to a 12-month follow-up period before efficacy and safety data will be available.
The final patient has been treated in the randomized, placebo controlled ProTrans-1 phase II part trial. Efficacy and safety data will be collected through regular clinical assessments visits during a 12 month period. Last patient, last will be assessed in July 2020 and thereafter the code will be
NextCell Pharma AB (NextCell) today treated the last diabetic patient in the phase II part of the ProTrans-1 trial. This means that all patients included in the clinical study have been treated and are now subject to a 12-month follow-up period before efficacy and safety data will be available.
T...
Read moreRead more2019-06-20
New collaboration and increased digital presence - Cellaviva is gearing for growth
NextCell Pharma AB ("NextCell") today announces that they, via its biobank Cellaviva, have entered into a partnership with Bonzun Health Information AB ("Bonzun"), who are providing the first global health app for pregnant women.
Bonzun has launched the first virtual midwife for pregnant women which can be downloaded in Appstores under the name Bonzun Pregnant. The app is currently available in 79 countries worldwide under the name Bonzun and in Sweden under the name Min Graviditet.
The collaboration has been entered into with the common goal of strengthening the work of sharing knowledge
NextCell Pharma AB ("NextCell") today announces that they, via its biobank Cellaviva, have entered into a partnership with Bonzun Health Information AB ("Bonzun"), who are providing the first global health app for pregnant women.
Bonzun has launched the first virtual midwife for pregnant women wh...
Read moreRead more